AWAndrew Wong

Andrew Wong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andrew Wong has a total of 217 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-effectiveness and budget impact of PFO closure: Cardioform vs Amplatzer and medical therapy for secondary stroke prevention in Australia

    by Gregory Starmer, Ross Sharpe, Andrew Wong, Hassan ElMarkaby, Timon Louwsma, Bianca Camuglia, David Fox

    The objective of this study was to evaluate the value of three secondary stroke prevention strategies in Australia: the Cardioform and Amplatzer Patent Foramen Ovale (PFO) closure devices, and medical management. An eight-state Markov model was employed to simulate a cohort of 1,000 patients with a history of PFO-associated stroke over a five-year time horizon. Treatment strategies included Cardioform, Amplatzer, and medical therapy alone. Effectiveness data were derived from the REDUCE and RESPECT trials, a matching-adjusted indirect comparison (MAIC), and prior cost-effectiveness studies. Costs, presented from an Australian healthcare perspective and expressed in 2023 AUD, were used to calculate quality-adjusted life-years (QALYs), strokes prevented, the incremental cost-effectiveness ratio (ICER), and net monetary benefit (NMB). Compared to Amplatzer, treatment with Cardioform yielded cost savings to the Australian health care systems (NMB of AUD 3.7 million) and improved patient outcomes (yielded 26.48 additional QALYs and prevented 28 more recurrent strokes). Relative to medical therapy alone, Cardioform resulted in improved patient outcomes and was cost-effective, with an ICER of $11,784/QALY. Cardioform provides an NMB of AUD 14.3 million and yielded 374.5 additional QALYs beside preventing 67 more strokes compared to medical therapy alone. Cardioform appears more cost-effective in the prevention of secondary PFO-associated strokes, supporting its adoption in clinical practice.


  • Open Access

    Integrated UPper limb and Language Impairment and Functional Training (UPLIFT) after stroke: study protocol for an umbrella Bayesian Optimal Phase IIa clinical trial

    by Kathryn S Hayward, Geoffrey Donnan, Erin Godecke, Anna Balabanski, Ruth Barker, Julie Bernhardt, Sandra Brauer, Amy Brodtmann, Emily Brogan, Sonia Brownsett, et al.

    Introduction: One in six stroke survivors continue to experience arm and language disability at 3 months post-stroke. This study aims to identify which model(s) of integrated UPper limb and Language Impairment and Functional Training (UPLIFT) show promise for people 3 months to 24 months post-stroke. We hypothesise that at least one promising UPLIFT model of rehabilitation will be identified. Methods and analysis: This is an adaptive Phase IIa master protocol umbrella design that includes four simultaneous Bayesian Optimal Phase II studies to evaluate individual UPLIFT interventions against prespecified objective performance criteria. The intervention is upper limb and language training at 2 or 4 hours/day, 5 days/week for 4 weeks, delivered either in person (severe stratum) or via telerehabilitation (mild–moderate stratum). Up to 160 adult participants will be recruited across six metropolitan/regional university or healthcare hubs spanning five Australian states. Baseline and post-intervention assessments are blinded. A promising response is defined as a composite binary outcome combining indicators of promise of efficacy, safety and feasibility. For each UPLIFT intervention, the proportion of participants with a promising response will be monitored at three equally spaced, predefined interim stopping points and one final analysis point (n=40 participants/study). An intervention will be stopped if too few promising responses are observed. Ethics and dissemination: Ethical approval was obtained from The Royal Melbourne Human Research Ethics Committee. All participating sites obtained local governance approval. All recruited participants will provide informed consent. Trial results will be disseminated through peer-reviewed publications and presented at major stroke and rehabilitation conferences. Trial registration number: ACTRN12622000373774.


  • Open Access

    Acute Dysphagia Following Reperfusion Therapies: A Prospective Pilot Cohort Study

    by Ellie Minchell, Anna Rumbach, Anna Farrell, Clare L. Burns, Andrew Wong, Emma Finch

    Dysphagia is a well-documented sequela of stroke. Recent advancements in medical treatments for stroke include reperfusion therapies (endovascular thrombectomy (EVT) and thrombolysis). As outcomes following reperfusion therapies are typically measured via general functional scales, the pattern and progression of acute dysphagia following reperfusion therapies is less known. To determine the progression of acute dysphagia (0–72 h) following reperfusion therapies and relationships between various stroke parameters and dysphagia, twenty-six patients were prospectively recruited across two EVT and thrombolysis centres in Brisbane, Australia. Dysphagia was screened via the Gugging Swallowing Screen (GUSS) at the bedside at three timepoints: 0–24 h, 24–48 h, and 48–72 h post-reperfusion therapies. Across three groups (EVT only, thrombolysis only, or both), the incidence of any dysphagia within the first 24 h of reperfusion therapy was 92.31% (n = 24/26), 91.30% (n = 21/23) by 48 h, and 90.91% (n = 20/22) by 72 h. Fifteen patients presented with severe dysphagia at 0–24 h, 10 at 24–48 h, and 10 at 48–72 h. Whilst dysphagia was not significantly correlated to infarct penumbra/core size, dysphagia severity was significantly related to the number of passes required during EVT (p = 0.009).Dysphagia continues to persist in the acute stroke population despite recent advancements in technology aimed to reduce morbidity and mortality post-stroke. Further research is required to establish protocols for management of dysphagia post-reperfusion therapies.


  • Ultra-Long Transfers for Endovascular Thrombectomy—Mission Impossible?: The Australia-New Zealand Experience

    by Carlos Garcia-Esperon, Teddy Y. Wu, Vinicius Carraro Do Nascimento, Bernard Yan, Craig Kurunawai, Tim Kleinig, Gregory Selkirk, David Blacker, P. Alan Barber, Annemarei Ranta, et al.

    Background: Endovascular thrombectomy (EVT) access in remote areas is limited. Preliminary data suggest that long distance transfers for EVT may be beneficial; however, the magnitude and best imaging strategy at the referring center remains uncertain. We hypothesized that patients transferred >300 miles would benefit from EVT, achieving rates of functional independence (modified Rankin Scale [mRS] score of 0–2) at 3 months similar to those patients treated at the comprehensive stroke center in the randomized EVT extended window trials and that the selection of patients with computed tomography perfusion (CTP) at the referring site would be associated with ordinal shift toward better outcomes on the mRS. Methods: This is a retrospective analysis of patients transferred from 31 referring hospitals >300 miles (measured by the most direct road distance) to 9 comprehensive stroke centers in Australia and New Zealand for EVT consideration (April 2016 through May 2021). Results: There were 131 patients; the median age was 64 [53–74] years and the median baseline National Institutes of Health Stroke Scale score was 16 [12–22]. At baseline, 79 patients (60.3%) had noncontrast CT+CT angiography, 52 (39.7%) also had CTP. At the comprehensive stroke center, 114 (87%) patients underwent cerebral angiography, and 96 (73.3%) proceeded to EVT. At 3 months, 62 patients (48.4%) had an mRS score of 0 to 2 and 81 (63.3%) mRS score of 0 to 3. CTP selection at the referring site was not associated with better ordinal scores on the mRS at 3 months (mRS median of 2 [1–3] versus 3 [1–6] in the patients selected with noncontrast CT+CT angiography, P =0.1). Nevertheless, patients selected with CTP were less likely to have an mRS score of 5 to 6 (odds ratio 0.03 [0.01–0.19]; P 300 miles, there was a benefit for EVT, with outcomes similar to those treated in the comprehensive stroke center in the EVT extended window trials. Remote hospital CTP selection was not associated with ordinal mRS improvement, but was associated with fewer very poor 3-month outcomes.


  • Open Access

    TACTICS - Trial of Advanced CT Imaging and Combined Education Support for Drip and Ship: evaluating the effectiveness of an ‘implementation intervention’ in providing better patient access to reperfusion therapies: protocol for a non-randomised controlled stepped wedge cluster trial in acute stroke

    by Annika Ryan, Christine L Paul, Martine Cox, Olivia Whalen, Andrew Bivard, John Attia, Christopher Bladin, Stephen M Davis, Bruce C V Campbell, Mark Parsons, et al.

    Introduction Stroke reperfusion therapies, comprising intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT), are best practice treatments for eligible acute ischemic stroke patients. In Australia, EVT is provided at few, mainly metropolitan, comprehensive stroke centres (CSC). There are significant challenges for Australia’s rural and remote populations in accessing EVT, but improved access can be facilitated by a ‘drip and ship’ approach. TACTICS (Trial of Advanced CT Imaging and Combined Education Support for Drip and Ship) aims to test whether a multicomponent, multidisciplinary implementation intervention can increase the proportion of stroke patients receiving EVT. Methods and analysis This is a non-randomised controlled, stepped wedge trial involving six clusters across three Australian states. Each cluster comprises one CSC hub and a minimum of three primary stroke centre (PSC) spokes. Hospitals will work in a hub and spoke model of care with access to a multislice CT scanner and CT perfusion image processing software (MIStar, Apollo Medical Imaging). The intervention, underpinned by behavioural theory and technical assistance, will be allocated sequentially, and clusters will move from the preintervention (control) period to the postintervention period. Primary outcome Proportion of all stroke patients receiving EVT, accounting for clustering. Secondary outcomes Proportion of patients receiving IVT at PSCs, proportion of treated patients (IVT and/or EVT) with good (modified Rankin Scale (mRS) score 0–2) or poor (mRS score 5–6) functional outcomes and European Quality of Life Scale scores 3 months postintervention, proportion of EVT-treated patients with symptomatic haemorrhage, and proportion of reperfusion therapy-treated patients with good versus poor outcome who presented with large vessel occlusion at spokes. Ethics and dissemination Ethical approval has been obtained from the Hunter New England Human Research Ethics Committee (18/09/19/4.13, HREC/18/HNE/241, 2019/ETH01238). Trial results will be disseminated widely through published manuscripts, conference presentations and at national and international platforms regardless of whether the trial was positive or neutral. Trial registration number ACTRN12619000750189; UTNU1111-1230-4161.


  • Brain activity during spoken word recognition in subacute aphasia

    by Tracy Roxbury, Katie McMahon, Andrew Wong, Anna Farrell, Penni Burfein, Shana Taubert, Kate O'BRien, Stephen Read, Alan Coulthard, David Copland


  • Open Access

    Emerging Spectra of Silent Brain Infarction

    by Jonathon P. Fanning, Allan J. Wesley, Andrew A. Wong, John F. Fraser


  • Vertebrobasilar dissections: Case series comparing patients with and without dissecting aneurysms

    by Monica S. Badve, Robert D. Henderson, John D. O’sullivan, Andrew A. Wong, Ken Mitchell, Alan Coulthard, Stephen J. Read